plaque psoriasis
Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
... reported in 6.6%–44.8% of patients. The presence of anti- adalimumab antibodies was associated with lower serum concentrations in 60% of the studies and reduced clinical efficacy in 80% of the studies reviewed. ...
8
Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
... Ixekizumab, the newest biologic agent approved for the treatment of moderate-to-severe plaque psoriasis, has demon- strated promising results in efficacy, safety, and quality-of-life improvement. Phase III ...
7
AYURVEDIC UNDERSTANDING AND MANAGEMENT OF KITIBHA KUSHTA (PLAQUE PSORIASIS) IN CHILDREN - A CASE REPORT .......
... Plaque Psoriasis is one among the different types of psoriasis. It is one of the most common type and af- fects almost 85%. It is characterised by dry, raised, red skin lesions or plaques covered ...
9
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
... Recently, preliminary data from IMMvent (NCT02694523) were presented. This was a Phase III randomized, double- blind, active-controlled study evaluating the efficacy and safety of risankizumab compared with adalimumab in ...
10
Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
... moderate-to-severe plaque psoriasis of at least 6 months, psoriasis involving at least 10% BSA, a PASI score of at least 12, and a static Physician’s Global Assessment (sPGA) score of at least ...
6
Endothelial Function and Inflammatory Activity in Patients with Recent Onset of Severe Plaque Psoriasis
... severe plaque psoriasis were ...the Psoriasis Area and Se- verity Index (PASI) ...with plaque phe- notype and a PASI-score above 12, representing severe pso- riasis [24], and with no pervious ...
5
Potential role of ustekinumab in the treatment of chronic plaque psoriasis
... severe plaque psoriasis in adults who fail to respond to or who have contraindications to, or are intolerant to other systemic agents, including cyclosporin, methotrexate, and ...
11
Etanercept in the treatment of plaque psoriasis
... RCT evaluating combination therapy with etanercept and methotrexate in 59 patients with plaque psoriasis who had previously failed methotrexate monotherapy. Patients were randomized into two groups, one ...
8
A Controlled Trial of Oral Rifampin in Chronic Plaque Psoriasis
... chronic plaque psoriasis (CPP) may revolutionize the therapeutic approach to this ...disease. Psoriasis with the hallmark of waxing and waning course can be more effectively prevented or treated by ...
7
EFFECT OF SITAGLIPTIN ON LIPID PROFILES AND THEIR CORRELATION WITH PASI SCORE IN PATIENTS WITH PLAQUE PSORIASIS
... with plaque psoriasis particularly those with high body mass index have increasing risk of developing a diabetes mellitus type 2 (DM2) and ...severe plaque psoriasis who were divided into two ...
8
<p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p>
... with plaque psoriasis, the most common form of psoriasis, typically include thick, scaly, erythematous, and well-circumscribed plaques that are often pruritic and ...painful. Psoriasis is also ...
8
Plaque Psoriasis: Understanding Risk Factors of This Inflammatory Skin Pathology
... Chronic plaque psoriasis is characterized by well-defined contour plaques, covered with whitish scaly skin, and which are most commonly found on the elbows, knees, lumbosacral area and scalp ...chronic ...
14
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
... Abstract: Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affects ...of psoriasis including TNF-alpha, IL-12, IL-17, and ...moderate–severe plaque psoriasis in the US, ...
8
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
... Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United ...of psoriasis have led to the development of targeted biologic therapies for this ...of ...
10
Evaluating practice patterns for managing moderate to severe plaque psoriasis
... severe plaque psoriasis, FPs were reported to play an impor- tant role in diagnosis and ongoing management of the ...with psoriasis, and the importance of an integrated “shared care” approach to ...
11
Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis : A Critique of the Evidence
... severe plaque psoriasis for at least 12 months prior to ...or psoriasis flare or rebound within 4 weeks of ...of psoriasis and its impact on physical, psychological and social functioning, ...
13
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
... Chronic plaque psoriasis presents clinically as an inflammatory disease of the skin, which is often associated with comorbidities and responsible for a poor quality of ...of psoriasis should be ...
8
<p>Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date</p>
... moderate-to-severe plaque psoriasis for more than six months before the initial dose of brodalu- ...by psoriasis of patients included in the study was greater than 10%, with a Psoriasis Area ...
11
INVESTIGATING THE EFFECT OF 1% CURCUMIN GEL AND PLACEBO ON PATIENTS WITH PLAQUE PSORIASIS
... of plaque, guttate, inverse, pustular, and ...moderate plaque psoriasis in a randomized and double-blind study as an inexpensive biologically active drug with ...
10
Therapeutic Class Overview : Psoriasis Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm
... Description: Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients' pain, function, and quality of life. ...
6